3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Prostatic Neoplasms
1
Adenocarcinoma
1
Acquired Immunodeficiency Syndrome
1
Interventions
Magnetic Resonance Spectroscopy
28
enzalutamide
23
Specimen Handling
20
apalutamide
17
Androgen Antagonists
14
Radiosurgery
13
Radiotherapy
12
Prednisone
12
Docetaxel
12
Abiraterone Acetate
12
abiraterone
10
Biopsy
10
Radiation
8
niraparib
6
luprolide acetate gel depot
6
darolutamide
6
Pluvicto
6
Leuprolide
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
relugolix
5
gallium 68 PSMA-11
5
cabazitaxel
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Nivolumab
5
Gonadotropin-Releasing Hormone
5
bicalutamide
4
Triptorelin Pamoate
4
Surveys and Questionnaires
4
Radiotherapy, Intensity-Modulated
4
Glutamate Carboxypeptidase II
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Transurethral Resection of Prostate
×
30 days
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn